Sign inJoin waitlistJoin the waitlist

Darla Liles

Physician · Brody Sch of Med at East Carolina Univ

Credentials: · · · ·

History

Brody Sch of Med at East Carolina Univ
Present

University of North Carolina School of Medicine
1992–1993
Pitt County Memorial Hospital
1989–1992
Internal Medicine
Brody School of Medicine at East Carolina University
1986–1989
Univ of Missouri, Kansas City Sch of Med
1982–1986

Research

Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease
New England Journal of Medicine · 2017 · 702 citations
PFA-100 system: a new method for assessment of platelet dysfunction
Seminars in Thrombosis and Hemostasis · 1998 · 355 citations
Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis
American Journal of Hematology · 2019 · 91 citations

Charles Knupp
8 papers
Nirmish Shah
7 papers
Victor Gordeuk
7 papers
JK
Julie Kanter
6 papers
Paul Walker
6 papers
Abdullah Kutlar
5 papers
Mahvish Muzaffar
5 papers · 1 as a fellow
Ana Antun
4 papers
Andrew Farland
4 papers
Ara Metjian
4 papers
BG
Briana Gibson
4 papers · 3 as a fellow
Camila Masias
4 papers

Grants

General Clinical Research Center
National Center for Research Resources · M01
Project lead · $721.5K · Univ of North Carolina Chapel Hill
1997–2002
Structure/Function Comparisons of Factor Ix and Factor x
National Heart, Lung, and Blood Institute · K08
Contact PI · $329.3K · East Carolina University
1995–2000
Site-Directed Mutagenesis of Factor Ix and Factor x
National Heart, Lung, and Blood Institute · F32
Contact PI · $35.3K · Univ of North Carolina Chapel Hill
1994

Clinical trials

A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
Site PI · Recruiting · Phase 1
Disc Medicine, Inc
2026–2027
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Site PI · Recruiting · Phase 3
Takeda
2025–2029
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027